Abbvie Inc Quick Ratio (ABBV) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Abbvie Inc   (NYSE: ABBV)

Abbvie Inc 's Quick Ratio

ABBV's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Abbvie Inc 's Cash & cash equivalent grew by 64.01 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Abbvie Inc 's Quick Ratio to 0.25, Quick Ratio remained below Abbvie Inc average.

Within Major Pharmaceutical Preparations industry 415 other companies have achieved higher Quick Ratio than Abbvie Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 3378, from total ranking in the second quarter 2026 at 4632.

Explain Quick Ratio?
How much Cash & cash equivalents ABBV´s has?
What are ABBV´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ABBV/financial-strength
https://api.csimarket.com/api/v1/companies/ABBV/fundamentals
https://api.csimarket.com/api/v1/companies/ABBV/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ABBV Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 9.42 %
Y / Y Cash & cash equivalent Change 89.98 %
Quick Ratio MRQ 0.25
ABBV's Total Ranking # 3378
Seq. Current Liabilities Change 3.51 %
Seq. Cash & cash equivalent Change 64.01 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 416
Healthcare Sector # 807
Overall Market # 3227


Quick Ratio Statistics
High Average Low
2.56 0.61 0.12
(Dec 31 2019)   (June 30. 2010)




Financial Statements
Abbvie Inc 's Current Liabilities $ 43,102 Millions Visit ABBV's Balance sheet
Abbvie Inc 's Cash & cash equivalent $ 10,774 Millions Visit ABBV's Balance sheet
Source of ABBV's Sales Visit ABBV's Sales by Geography


Cumulative Abbvie Inc 's Quick Ratio

ABBV's Quick Ratio for the trailling 12 Months

ABBV Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 10.25 %
Y / Y Cash & cash equivalent TTM Growth 39.89 %
Quick Ratio TTM 0.19
Total Ranking TTM # 3017
Seq. Current Liabilities TTM Growth 2.23 %
Seq. Cash & cash equivalent TTM Growth 18.98 %

Quick ratio ranking by company, industry and sector >> Back to ABBV Financial Strength Comparisons >> Go to Compare ABBV Quick Ratio to its Competitors

On the trailing twelve months basis ABBV Cash & cash equivalent soared by 89.98 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Abbvie Inc 's Quick Ratio to 0.19, Quick Ratio remained below ABBV average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 443 other companies have achieved higher Quick Ratio than Abbvie Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending second quarter 2026 at 4105.

Explain Quick Ratio?
How much Cash & cash equivalents ABBV´s has?
What are ABBV´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 444
Healthcare Sector # 910
Within the Market #


trailing twelve months Quick Ratio Statistics
High Average Low
1.46 0.54 0.14
(Mar 31 2020)   (Dec 31 2025)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Ionis Pharmaceuticals Inc   0.68 $ 296.303  Millions$ 435.292  Millions
Liquidia Corporation  0.68 $ 396.091  Millions$ 585.397  Millions
Bristol myers Squibb Company  0.67 $ 12,581.000  Millions$ 18,753.000  Millions
Harrow Inc   0.66 $ 75.336  Millions$ 114.224  Millions
Supernus Pharmaceuticals inc   0.62 $ 176.171  Millions$ 285.397  Millions
Axsome Therapeutics Inc   0.62 $ 313.859  Millions$ 509.719  Millions
Travere Therapeutics Inc   0.59 $ 123.542  Millions$ 210.912  Millions
Clene Inc   0.58 $ 9.887  Millions$ 17.114  Millions
Zoetis Inc   0.57 $ 1,533.000  Millions$ 2,682.000  Millions
Organon and Co   0.55 $ 1,455.000  Millions$ 2,652.000  Millions
Medicus Pharma Ltd   0.52 $ 5.020  Millions$ 9.743  Millions
Gossamer Bio Inc   0.51 $ 51.189  Millions$ 99.945  Millions
Bausch Health Companies Inc   0.51 $ 2,485.000  Millions$ 4,895.000  Millions
Neonc Technologies Holdings Inc   0.49 $ 10.966  Millions$ 22.241  Millions
Inovio Pharmaceuticals Inc   0.48 $ 49.786  Millions$ 102.842  Millions
Avenue Therapeutics Inc   0.47 $ 1.520  Millions$ 3.210  Millions
Royalty Pharma Plc  0.46 $ 544.857  Millions$ 1,179.003  Millions
Zymeworks Inc   0.45 $ 100.464  Millions$ 223.931  Millions
Organogenesis Holdings Inc   0.45 $ 21.326  Millions$ 47.649  Millions
Inmed Pharmaceuticals Inc  0.43 $ 1.140  Millions$ 2.673  Millions
Kiniksa Pharmaceuticals International Plc  0.43 $ 81.660  Millions$ 191.855  Millions
Syndax Pharmaceuticals Inc   0.40 $ 146.094  Millions$ 361.833  Millions
Vanda Pharmaceuticals Inc   0.40 $ 62.038  Millions$ 154.980  Millions
Kura Oncology Inc   0.39 $ 57.937  Millions$ 148.730  Millions
Ultragenyx Pharmaceutical Inc   0.39 $ 150.000  Millions$ 389.000  Millions
Biomarin Pharmaceutical Inc  0.38 $ 736.007  Millions$ 1,913.942  Millions
Earth Science Tech Inc   0.38 $ 1.009  Millions$ 2.639  Millions
Aurinia Pharmaceuticals Inc   0.36 $ 45.792  Millions$ 127.629  Millions
Merck and Co Inc   0.34 $ 9,650.000  Millions$ 28,801.000  Millions
Cytodyn inc   0.33 $ 16.359  Millions$ 49.700  Millions

Date modified: 2026-11-04T15:04:13+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.